Tirzepatide for Weight Loss
The FDA recently approved tirzepatide for use in improving blood sugar control in patients with type 2 diabetes. Results of the SURMOUNT-1 trial were presented at #ADA2022. They showed tirzepatide's efficacy for weight loss in patients without diabetes. The findings were called "unprecedented" and sparked a wave of impressed reactions, leading to this week's top trending clinical topic. SURMOUNT-1 was a placebo-controlled trial that included more than 2500 participants with obesity or overweight who had at least one weight-related complication. At baseline, the mean body weight was 231 lb (104.8 kg) and the mean BMI was 38. Study results at 72 weeks of treatment showed : • The mean percentage change in weight was −15% (95% CI, −15.9 to −14.2) with 5-mg weekly doses of tirzepatide, −19.5% (95% CI, −20.4 to −18.5) with 10-mg doses, and −20.9% (95% CI, −21.8 to −19.9) with 15-mg doses. • Weight reduction of 5% or more was reported in 85% (95% CI, 82% -89%) of the 5-mg group, 89% (95% CI, 86% -92%) of the 10-mg group, and 91% (95% CI, 88% -94%) of the 15-mg group. • In the 10-mg and 15-mg groups, 50% (95% CI, 46% -54%) and 57% (95% CI, 53% -61%) of participants, respectively, had a reduction in body weight of 20% or more . Experts pointed out that they are in the range of weight loss achieved with bariatric surgery. The authors of an accompanying editorial stated, "It is remarkable that the magnitude of weight loss with tirzepatide was similar to that with gastric bypass, which raises the potential for alternative medical approaches to the treatment of obesity."
Source: https://www.instagram.com/p/CfgqUk8OQJW/?igshid=YmMyMTA2M2Y=